| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| License and collaboration revenue | 16 | - | ||
| Research and development expense | 11,110 | - | ||
| General and administrative expense | 6,583 | - | ||
| Total operating expenses | 17,693 | - | ||
| Loss from operations | -17,677 | - | ||
| Interest income | 545 | - | ||
| Other income (expense) | -7 | - | ||
| Total other income, net | 538 | - | ||
| Net loss before income tax | -17,139 | -12,844 | ||
| Income tax expense | 61 | 55 | ||
| Net loss | -17,200 | -12,899 | ||
| Foreign currency translation adjustments | 87 | 236 | ||
| Unrealized gains on available-for-sale investments | 11 | -6 | ||
| Comprehensive loss | -17,102 | -12,669 | ||
| Basic net loss per ordinary share (in dollars per share) | -0.31 | -0.23 | ||
| Diluted net loss per ordinary share (in dollars per share) | -0.31 | -0.23 | ||
| Weighted-average ordinary shares outstanding, basic (in shares) | 55,716,000 | 55,498,000 | ||
| Weighted-average ordinary shares outstanding, diluted (in shares) | 55,716,000 | 55,498,000 | ||
Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd (CNTB)